There are currently 38 active clinical trials seeking participants for Asthma research studies. The states with the highest number of trials for Asthma participants are .
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma
NCT05222529
Recruiting
The purpose of this study is to characterize the bronchodilator effect, systemic exposure and safety/tolerability of two different doses of inhaled glycopyrronium, when compared to placebo. Outcome of this study will be used to determine the dose of inhaled glycopyrronium for the development of fixed dose combination indacaterol/mometasone/glycopyrronium (QVM149) for children aged 6 to less than 12 years old with moderate to severe asthma.
Gender:
ALL
Ages:
Between 6 years and 11 years
Trial Updated:
07/29/2025
Locations: Novartis Investigative Site, Ruse, Not set +22 locations
Conditions: Asthma
Register for Updates
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
NCT06637371
Recruiting
The main objective of this study is to assess the safety and tolerability of AMG 691 as single doses (healthy participants only) and multiple doses in healthy participants and participants with mild-to-moderate asthma.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/24/2025
Locations: Orange County Research Center, Lake Forest, California +10 locations
Conditions: Asthma
Register for Updates
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
NCT05692180
Recruiting
A study to evaluate the efficacy and safety of benralizumab administered subcutaneously in patients ≥ 6 to \< 18 years of age with severe eosinophilic asthma, including a well-documented history of asthma exacerbations and uncontrolled asthma receiving high-dose inhaled corticosteroid (ICS) plus at least one additional controller medication.
Gender:
ALL
Ages:
Between 6 years and 18 years
Trial Updated:
07/16/2025
Locations: Research Site, Mobile, Alabama +86 locations
Conditions: Asthma
Register for Updates
Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
NCT03953300
Recruiting
The purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics. Changes will be assessed over 48 week treatment period in patients with persistent symptoms despite standard therapy of inhaled corticosteroids (ICS) plus long acting B2-agonist (LABA) with or without additional controller medication. Patients who complete treatment will enter 4 weeks follow-up period.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/14/2025
Locations: Research Site, Birmingham, Alabama +52 locations
Conditions: Asthma
Register for Updates
A Trial Evaluating Novel Technologies for the Diagnosis of Asthma The LUNG-TECH Trial
NCT05819944
Recruiting
This trial aims to evaluate novel diagnostic technologies for asthma in 3 different pathways providing the necessary evidence-base to allow adoption into clinical practice: * Pathway 1 evaluates whether the technology can distinguish between people with asthma and healthy volunteers, and other respiratory conditions in a well characterised secondary-care population and whether the parameters they measure correlate with the current standard diagnostic tests; * Pathway 2 assesses whether the tech... Read More
Gender:
ALL
Ages:
17 years and above
Trial Updated:
07/14/2025
Locations: Portsmouth Hospitals University NHS Trust, Portsmouth, Hampshire
Conditions: Asthma
Register for Updates
A Comparison of Diagnostic Testing Modalities in the Assessment of Asthma
NCT06286085
Recruiting
This study aims to assess the concordance of international asthma guidelines in the diagnosis of asthma and explore the presence of airways disease using additional non-guideline physiologic criteria, such as IOS (impulse osciollometry), not included in the guidelines, but available in the Portsmouth lung function service.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Portsmouth Hospitals University NHS Trust, Portsmouth, Not set
Conditions: Asthma
Register for Updates
A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations
NCT06529419
Recruiting
A dose range-finding study to assess the efficacy and safety of multiple dose levels of AZD8630 administered via a dry powder inhaler in adults with uncontrolled asthma at risk of exacerbations, receiving medium -to -high dose inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/16/2025
Locations: Research Site, Mesa, Arizona +231 locations
Conditions: Asthma
Register for Updates
Reducing Chronic Breathlessness in Adults by Following a Self-guided, Internet Based Supportive Intervention (SELF-BREATHE)
NCT06326957
Recruiting
Background: Some health conditions make breathing difficult and uncomfortable. When this happens every day, it is called chronic breathlessness. Over 3 million people living with heart and lung disease have chronic breathlessness in the UK. Breathlessness is very difficult for patients themselves and their families, resulting in disability and feelings of fear, distress, and isolation. Due a to lack of supportive breathlessness services many patients frequently attend hospital Accident and Eme... Read More
Gender:
ALL
Ages:
Between 18 years and 110 years
Trial Updated:
06/10/2025
Locations: King's College Hospital NHS Foundation Trust, London, Not set
Conditions: Chronic Obstructive Pulmonary Disease, Bronchiectasis, Interstitial Lung Disease, Lung Cancer, Asthma, Dyspnea, Fibrotic Lung Disease, Chronic Lung Disease
Register for Updates
A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive
NCT06433921
Recruiting
The primary objectives of the study are: Part 1: to characterize the potency and variability of dose response on efficacy (Provocative concentration of methacholine causing at least a 20% fall in forced expiratory volume (FEV1) \[PC20\]) of salbutamol administered via MDI with salbutamol HFA-134a or salbutamol HFA-152a in participants with mild asthma. Part 2: to compare the comparative dose response on efficacy (PC20) of salbutamol when administered via MDI with salbutamol HFA-134a or salbutamo... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/08/2025
Locations: GSK Investigational Site, Manchester, Not set
Conditions: Asthma, Mild Asthma
Register for Updates
The Extended Salford Lung Study ("Ex-SLS") Data Access Project
NCT03152669
Recruiting
The Salford Lung Study (SLS) subjects represent a group of COPD and asthma patients whose disease is extremely well-characterised over a short time period. Subjects in the SLS originally consented for information relevant to the study to be shared with the sponsor (GSK). These data were limited to three years prior to randomisation and the twelve-month interventional treatment period. Broadened access to patients' data would allow SLS subjects' entire disease journey to be researched, presenting... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: GSK Investigational Site, Manchester, Not set
Conditions: Asthma
Register for Updates
EMPOWER-1: A Multi-site Clinical Cohort Research Study to Reduce Health Inequality
NCT03987633
Recruiting
Health inequality and genetic disparity are a significant issue in the United Kingdom (UK). This study focuses on diseases that are associated with significant morbidity and mortality in the UK, and specifically examines the extent and basis of treatment failure in different patient populations. The vast majority of drug registration clinical trials have under-representation of ethnic minority populations. In addition, the wider Caucasian populations have reasonably different clinical characte... Read More
Gender:
ALL
Ages:
6 years and above
Trial Updated:
03/05/2025
Locations: Future Genetics, The Science Centre, Wolverhampton Science Park, Wolverhampton, West Midlands
Conditions: Atrial Fibrillation, Coronary Heart Disease, Cardiovascular Diseases, Heart Failure, Hypertension, Peripheral Arterial Disease, Stroke, Ischemic, Asthma, Chronic Obstructive Pulmonary Disease, Obesity, Cancer, Chronic Kidney Diseases, Diabetes Mellitus, Dementia, Depression, Epilepsy, Mental Health Disorder, Rheumatoid Arthritis, Blood Pressure, Breast Cancer Risk, Prostate Cancer, Lung Cancers
Register for Updates
Exploring the Lived Experience of Young Adults With Severe Asthma
NCT06681545
Recruiting
Asthma is a serious long-term lung condition caused by swollen airways that narrow. This causes wheezing, chest tightness, and breathlessness. Most asthma is well-controlled with medication. However, 5-10% of asthmatics have severe asthma where treatment does not control symptoms and up to 67% of asthmatics have uncontrolled asthma, caused by not always taking medication as recommended, lifestyle choices or other health problems worsening their asthma. In the UK, asthma affects around 800,000... Read More
Gender:
ALL
Ages:
Between 16 years and 25 years
Trial Updated:
02/03/2025
Locations: Severe asthma services based at both Manchester University Foundation NHS trust and Liverpool University Foundation NHS Trust, Manchester, Greater
Conditions: Asthma, Severe Asthma, Uncontrolled Asthma
Register for Updates